Biocartis is at the forefront of molecular testing technology with its Idylla™ platform, a fully automated system designed to deliver rapid and accurate molecular biomarker results in as little as three hours. This innovative platform utilizes real-time PCR technology and is equipped with contamination-controlled, airtight disposable cartridges that integrate all necessary reagents and controls. The Idylla system is designed for ease of use, requiring minimal hands-on time, and is suitable for any laboratory setting, making it a versatile tool for oncologists and pathologists alike. The platform is CE-marked in Europe and has received 510(k) clearance in the United States, underscoring its compliance with regulatory standards.

The Idylla platform supports a wide range of oncology tests, including assays for various mutations associated with breast, colorectal, and other cancers. These assays, such as the Idylla EGFR Mutation Assay and the Idylla GeneFusion Assay, enable the detection of multiple genetic mutations from a single sample, facilitating personalized medicine approaches. Biocartis also emphasizes the importance of research and collaboration, encouraging the exploration of new biomarkers and offering research assays for emerging uses. This commitment to innovation and accessibility positions Biocartis as a key player in the advancement of molecular diagnostics in oncology.

Belgium

Biocartis is a molecular diagnostics company that revolutionizes testing with its proprietary IdyllaTM Platform, offering next-generation diagnostic solutions to enhance clinical practice and patient outcomes.

Biocartis

Company Details